Roughly one in ten people prescribed a statin to protect their heart ends up stopping the medication because their muscles hurt too much to continue. That statistic has sat unresolved in cardiology for decades – doctors knew statin muscle pain was real, they just couldn’t see exactly what was causing it inside the cell. Two separate research teams, working independently, published findings within weeks of each other in late 2025 and early 2026 that finally changed that.
The drugs in question are among the most prescribed in the world. Statins lower LDL cholesterol (the type that builds up as plaque inside artery walls) by blocking a liver enzyme called HMG-CoA reductase, as explained in reference material from the NIH. Less enzyme activity means less cholesterol is manufactured in the liver, which means less cholesterol circulates in the blood. For tens of millions of people, this mechanism prevents heart attacks and strokes. The problem has always been that the same drugs that protect the heart appear to do something harmful to skeletal muscle – the tissue in your arms, legs, and back that you use to move.
For years, researchers suspected the mechanism involved calcium, the mineral that flows into muscle fibers to trigger contractions. What they lacked was the atomic-level picture of exactly how a statin molecule could open a calcium channel and why that opening caused damage. That picture now exists.
The Calcium Channel Nobody Was Watching
To uncover the mechanism, researchers turned to cryo-electron microscopy – an advanced imaging method that allows scientists to see proteins in near-atomic detail. Using this technique, they observed how statins interact with a key muscle protein known as the ryanodine receptor, or RyR1. This protein regulates the flow of calcium inside muscle cells, acting as a gate that opens only when muscles need to contract.
When statins bind to RyR1, they force the channel into an open position. This causes calcium to leak continuously, which can be toxic to muscle tissue and lead to damage. The gate that is supposed to open briefly and then snap shut stays open. Calcium floods in when it shouldn’t, and the muscle pays the price.
The researchers discovered that statins bind to the ryanodine receptor in an unusual way. Three statin molecules cluster together inside a pocket of the protein. The first molecule binds while the channel is closed, setting the stage for it to open. Two additional molecules then lodge into place, forcing the channel fully open.
The calcium leak could explain the muscular side effects of statins either by weakening the muscle directly or by activating enzymes that degrade muscle tissue. In other words, the downstream damage comes from two directions: the calcium itself is toxic at elevated concentrations inside muscle cells, and the flood of calcium also switches on the cell’s own demolition crew, enzymes that begin breaking down muscle fiber from within.
This finding came from a November 2025 study published in Nature Communications by researchers at the University of British Columbia and the University of Wisconsin-Madison. “This is the first time we’ve had a clear picture of how statins activate this channel,” said Dr. Filip Van Petegem, senior author and professor at UBC’s Life Sciences Institute. “It’s a big step forward because it gives us a roadmap for designing statins that don’t interact with muscle tissue.”
A separate Columbia University team published complementary findings in the Journal of Clinical Investigation in December 2025. Their imaging revealed two locations on the ryanodine receptor where simvastatin binds, opening a channel in the receptor and allowing calcium to flow through. The calcium leak, according to lead researcher Dr. Andrew Marks, may explain the muscular side effects of statins by weakening muscle directly or by activating enzymes that degrade muscle tissue.
How Common Is Statin Muscle Pain, Really?
Statin-associated muscle symptoms, known as SAMS, are the leading cause of statin discontinuation, potentially undermining cardiovascular protection. The clinical picture is messier than it might appear, though.
Approximately 10% of individuals develop statin-associated muscle symptoms when all reported cases are counted, regardless of whether the statin was genuinely responsible. The actual share of cases driven by the drug’s pharmacology is considerably smaller. The prevalence of all muscle symptoms temporally related to statin use is estimated at around 10%, but the prevalence of pharmacological SAMS – symptoms genuinely caused by the drug – is about 1 to 2%. A 2022 meta-analysis pooling data from 154,664 participants across 23 trials suggested that more than 90% of SAMS were not pharmacological, with a placebo-corrected prevalence of pharmacological SAMS of around 0.5%.
That finding doesn’t mean patients reporting pain are imagining things. Researchers refer to the phenomenon behind many of these reported symptoms as the “nocebo effect” – the opposite of a placebo. Cases of muscle pain and weakness may be due to the nocebo effect, where the expectation of side effects makes patients more likely to report them. Knowing that a drug has a reputation for causing muscle pain can actually make you feel muscle pain, even if the drug isn’t causing it.
For patients in whom the statin is genuinely responsible, myalgia (muscle aching) is the most frequent manifestation, and the risk of muscle symptoms is greatest within the first year of therapy. Symptoms tend to appear in the thighs, calves, or shoulders and are often described as a diffuse soreness rather than the sharp pain of an injury.
Not All Statins Are Equal
Certain statins, including simvastatin, can bind to RyR1 in a way that destabilizes the channel. The research from the UBC team suggests this is not an isolated quirk of one drug – it applies across the class. According to a 2022 study in Pharmacological Research, RyR1 activation appears to be a class effect of all commonly prescribed statins, including atorvastatin. The same research identified cerivastatin, a statin withdrawn from the market in 2001 because of severe muscle side effects, as a particularly strong activator of RyR1 channels – which, in retrospect, explains why its side effect profile was so dangerous.
While statins are generally safe, rhabdomyolysis from statins is uncommon and most likely to occur at high doses or when combined with certain other drugs. Rhabdomyolysis (pronounced rab-doe-my-OL-ih-sis) is the most severe end of the statin muscle damage spectrum. It’s a rare but serious side effect involving the breakdown of muscle tissue, which releases substances into the bloodstream that can cause kidney damage. Specifically, rhabdomyolysis involves skeletal muscle tissue breaking down rapidly, releasing intracellular contents such as myoglobin and creatine kinase into the blood. Myoglobin, a protein that gives muscle its red color, is toxic to the kidneys when it floods the bloodstream in large amounts. The syndrome is characterized by this release of intracellular components into the bloodstream and can lead to systemic complications including acute kidney injury, electrolyte disturbances, and disseminated intravascular coagulation.
Muscle pain that is unusually severe, accompanied by dark or cola-colored urine, or that doesn’t resolve within a few days of stopping the drug warrants urgent medical attention. In severe cases, dialysis may be required if acute kidney injury develops.
If you’re currently taking a statin and managing side effects, it’s worth reading about the most common statin side effects to understand the full picture of what to watch for and when to act.
A Decades-Old Question, a New Answer
The long gap between statins entering widespread use and scientists understanding their muscle mechanism wasn’t due to lack of effort. The ryanodine receptor is an enormous, complex protein – difficult to image and difficult to study in live tissue. Cryo-electron microscopy, which involves rapidly freezing biological samples and analyzing them with electron beams to reconstruct three-dimensional molecular structures, only became powerful enough to capture the interaction in the detail required relatively recently. Researchers at the University of British Columbia, working with colleagues at the University of Wisconsin-Madison, uncovered the biological reason behind these side effects using exactly this technique.
The practical implication is significant. By altering only the parts of the drug that interact with RyR1, scientists hope to retain cholesterol-lowering benefits while minimizing muscle toxicity. The Columbia team is pursuing a parallel approach: Dr. Marks is now collaborating with chemists to create such a statin. Plugging the calcium leak could be another option – statin-induced calcium leaks in mice can be closed, the researchers showed, with an experimental drug developed in the Marks lab.
These experimental compounds, known as Rycals, work by stabilizing the ryanodine receptor and preventing it from leaking calcium. According to reporting from SciTechDaily, Rycals helped stabilize the calcium channel, preventing leaks and reducing muscle weakness in mouse models. They are not yet approved for human use, but the mouse results provide proof of concept that the calcium pathway is the right target.
Read More: Your Daily Statin May Be Depleting This Essential Nutrient
What This Means for You
If you take a statin and experience muscle aching, fatigue, or weakness, don’t stop the medication abruptly. Tell your doctor. The first step is usually to rule out whether the symptoms are genuinely drug-related, which can be done through a supervised “dechallenge” – stopping the drug temporarily to see if symptoms resolve – or by switching to a different statin at a lower dose. Restarting statin therapy after a muscle-related event is possible, but must be carefully considered. Each case should be evaluated individually, weighing the cardiovascular benefits of statin therapy against the risk of recurrence.
For patients who cannot tolerate any statin at any dose, non-statin cholesterol-lowering therapies now exist, including PCSK9 inhibitors and bempedoic acid, which work through different pathways and do not appear to carry the same muscle risk. A frank conversation with your doctor about alternatives is reasonable if statin muscle pain has made you consider stopping treatment altogether.
The research coming out of UBC and Columbia represents a genuine turning point. For the first time, the mechanism behind statin muscle pain is visible at the molecular level. Redesigned statins that avoid binding RyR1 – or drugs that seal the calcium leak after it starts – could, within the next decade, make this side effect a solved problem rather than a reason to abandon heart-protective therapy.
Disclaimer: This information is not intended to be a substitute for professional medical advice, diagnosis, or treatment and is for information only. Always seek the advice of your physician or another qualified health provider with any questions about your medical condition and/or current medication. Do not disregard professional medical advice or delay seeking advice or treatment because of something you have read here.
AI Disclaimer: This article was created with the assistance of AI tools and reviewed by a human editor.